- Investor's Business Daily•5 hours ago
Regeneron and Sanofi argue Amgen's patents covering LDL-buster Repatha are too broad.
- GlobeNewswire•8 hours ago
Suliqua TM Approved in the European Union for the Treatment of Adults with Type 2 Diabetes Paris, France - January 18th , 2017 - Sanofi announced today that the European Commission has granted marketing ...
Reporting EN This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible ...
SAN.PA : Summary for SANOFI - Yahoo Finance
Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's Range||75.85 - 76.99|
|52 Week Range||62.50 - 79.07|
|PE Ratio (TTM)||23.36|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|